董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ian Huen | 男 | Chairman and Chief Executive Officer and Director | 45 | 98.73万美元 | 211.41 | 2026-07-20 |
| Justin Wu | 男 | Independent Non-Executive Director | 55 | 8.77万美元 | 未持股 | 2026-07-20 |
| Douglas Arner | 男 | Independent Non-Executive Director | 55 | 8.77万美元 | 未持股 | 2026-07-20 |
| Kira Sheinerman | 女 | Executive Director and Secretary and Treasurer | 56 | 未披露 | 未持股 | 2026-07-20 |
| Laura A. Philips | 女 | Independent Non-Executive Director | 68 | 未披露 | 未持股 | 2026-07-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary Anthony | 男 | Chief Financial Officer | 65 | 未披露 | 未持股 | 2026-07-20 |
| Ian Huen | 男 | Chairman and Chief Executive Officer and Director | 45 | 98.73万美元 | 211.41 | 2026-07-20 |
| Alidad Mireskandari | 男 | Chief Operation Officer and President | 58 | 15.77万美元 | 未持股 | 2026-07-20 |
| Alidad Mireskandari | 男 | Chief Operation Officer and President | 57 | 未披露 | 未持股 | 2026-07-20 |
| Kira Sheinerman | 女 | Executive Director and Secretary and Treasurer | 56 | 未披露 | 未持股 | 2026-07-20 |
董事简历
中英对照 | 中文 | 英文- Ian Huen
-
Ian Huen是知临集团的创始人、首席执行官和执行董事。Huen先生自2005年以来也是香港公司Aeneas Capital Limited的联合创始人，Aeneas Capital Limited是一家受香港证券及期货事务监察委员会监管的第9类资产管理公司。他拥有超过17年的全球资产管理经验，此前曾担任Janus Henderson Group plc（前身为Janus Capital）的股票研究分析师，负责美国梦百合行业。Huen先生于二零零七年担任澳门恒生银行有限公司出售予中国工商银行的财务顾问，并获委任为工商银行董事局Vice President及中国商业银行澳门资本有限公司于2007年3月发行，期限12年，至2019年3月止。
Ian Huen is the Founder, Chief Executive Officer and an Executive Director of Aptorum Group Limited. Mr. Huen previous served as Non Executive Director of Aptorum Group from June 2022 to November 2023, and as Chief Executive Officer and Executive Director of Aptorum Group Limited from October 2017 to May 2022. He has extensive experience in global asset management and previously covered the U.S. healthcare sector as an equity research analyst at Janus Henderson Group plc (formerly known as Janus Capital). Mr. Huen was the financial advisor in the sale of Seng Heng Bank Limited (Macau) to Industrial and Commercial Bank of China in 2007 and was appointed as the vice president of the Board of General Meeting in Industrial and Commercial Bank of China (Macau) Capital Limited in March 2007 for a term of 12 years until March 2019. As a trustee board member of the Dr. Stanley Ho Medical Development Foundation, Mr. Huen facilitates advisory, development funding, access to research resources across Asia and continues to establish relationships with leading academic institutions to propel innovations in healthcare. - Ian Huen是知临集团的创始人、首席执行官和执行董事。Huen先生自2005年以来也是香港公司Aeneas Capital Limited的联合创始人，Aeneas Capital Limited是一家受香港证券及期货事务监察委员会监管的第9类资产管理公司。他拥有超过17年的全球资产管理经验，此前曾担任Janus Henderson Group plc（前身为Janus Capital）的股票研究分析师，负责美国梦百合行业。Huen先生于二零零七年担任澳门恒生银行有限公司出售予中国工商银行的财务顾问，并获委任为工商银行董事局Vice President及中国商业银行澳门资本有限公司于2007年3月发行，期限12年，至2019年3月止。
- Ian Huen is the Founder, Chief Executive Officer and an Executive Director of Aptorum Group Limited. Mr. Huen previous served as Non Executive Director of Aptorum Group from June 2022 to November 2023, and as Chief Executive Officer and Executive Director of Aptorum Group Limited from October 2017 to May 2022. He has extensive experience in global asset management and previously covered the U.S. healthcare sector as an equity research analyst at Janus Henderson Group plc (formerly known as Janus Capital). Mr. Huen was the financial advisor in the sale of Seng Heng Bank Limited (Macau) to Industrial and Commercial Bank of China in 2007 and was appointed as the vice president of the Board of General Meeting in Industrial and Commercial Bank of China (Macau) Capital Limited in March 2007 for a term of 12 years until March 2019. As a trustee board member of the Dr. Stanley Ho Medical Development Foundation, Mr. Huen facilitates advisory, development funding, access to research resources across Asia and continues to establish relationships with leading academic institutions to propel innovations in healthcare.
- Justin Wu
-
Justin Wu是知临集团的独立非执行董事。自2018年8月起，他还一直担任中大医疗中心首席运营官。他于2014年7月至2018年6月担任中大医学院副院长，并于2012年12月至2014年7月担任中大医学院临床副院长并自2009年以来一直担任医学和治疗学系教授也是S.H.Ho消化健康中心的主任，该中心是一家研究中心，专门从事功能性胃肠道疾病，反流和运动障碍以及消化内窥镜检查。吴博士活跃于研究出版物和评估，曾担任美国胃肠病学杂志“；AJG”；的国际副编辑，以及胃肠病学和肝病学杂志（“；JGH”；）的执行编辑。他也是亚洲神经胃肠病学和运动协会（“；Anma”；）的秘书长，以及亚太胃肠病学协会（“；Apage”；）的秘书长。
Justin Wu is an Independent Non Executive Director of Aptorum Group Limited. He also has been serving as the Chief Operating Officer of CUHK Medical Centre since August 2018. He served as the Associate Dean (Development) of the Faculty of Medicine at CUHK from July 2014 to June 2018 and the Associate Dean (Clinical) of the Faculty of Medicine at CUHK from December 2012 to July 2014, and has been serving a Professor in the Department of Medicine and Therapeutics since 2009, also the Director of the S. H. Ho Center for Digestive Health, a research center specializing in functional gastrointestinal diseases, reflux and motility disorders, and digestive endoscopy. Active in research publications and assessments, Professor Wu served as the International Associate Editor of American Journal of Gastroenterology ("AJG"), and Managing Editor of Journal of Gastroenterology and Hepatology ("JGH"). He is also the Secretary General of the Asian Neurogastroenterology and Motility Association ("ANMA"), and Secretary General of the Asia Pacific Association of Gastroenterology ("APAGE").Professor Wu has won a number of awards including the Emerging Leader in Gastroenterology Award by the JGH Foundation, and the Vice Chancellor's Exemplary Teaching Award at CUHK. Aside from his expertise in gastroenterology, Professor Wu has an extensive interest in the development of Integrative Medicine in Hong Kong. He is the Founding Director of the Hong Kong Institute of Integrative Medicine, working closely with the School of Chinese Medicine to develop an integrative model at an international level. The institute aims at maximizing the strength of Western and Chinese medicine to provide a safe and effective integrative treatment to patients.Professor Wu served as a consultant and an advisory board member for Takeda Pharmaceutical, AstraZeneca, Menarini, Reckitt Benckiser and Abbott Laboratory. He earned his Bachelor of Medicine and Bachelor of Surgery Degree (1993), and his Doctor of Medicine Degree (2000) from CUHK. Additionally, he attained Fellowships of the Royal College of Physicians of Edinburgh and London in 2007 and 2012 respectively, Fellowship of the Hong Kong College of Physicians in 2002, Fellowship of the Hong Kong Academy of Medicine in 2002, and has been an American Gastroenterological Association Fellow since 2012. - Justin Wu是知临集团的独立非执行董事。自2018年8月起，他还一直担任中大医疗中心首席运营官。他于2014年7月至2018年6月担任中大医学院副院长，并于2012年12月至2014年7月担任中大医学院临床副院长并自2009年以来一直担任医学和治疗学系教授也是S.H.Ho消化健康中心的主任，该中心是一家研究中心，专门从事功能性胃肠道疾病，反流和运动障碍以及消化内窥镜检查。吴博士活跃于研究出版物和评估，曾担任美国胃肠病学杂志“；AJG”；的国际副编辑，以及胃肠病学和肝病学杂志（“；JGH”；）的执行编辑。他也是亚洲神经胃肠病学和运动协会（“；Anma”；）的秘书长，以及亚太胃肠病学协会（“；Apage”；）的秘书长。
- Justin Wu is an Independent Non Executive Director of Aptorum Group Limited. He also has been serving as the Chief Operating Officer of CUHK Medical Centre since August 2018. He served as the Associate Dean (Development) of the Faculty of Medicine at CUHK from July 2014 to June 2018 and the Associate Dean (Clinical) of the Faculty of Medicine at CUHK from December 2012 to July 2014, and has been serving a Professor in the Department of Medicine and Therapeutics since 2009, also the Director of the S. H. Ho Center for Digestive Health, a research center specializing in functional gastrointestinal diseases, reflux and motility disorders, and digestive endoscopy. Active in research publications and assessments, Professor Wu served as the International Associate Editor of American Journal of Gastroenterology ("AJG"), and Managing Editor of Journal of Gastroenterology and Hepatology ("JGH"). He is also the Secretary General of the Asian Neurogastroenterology and Motility Association ("ANMA"), and Secretary General of the Asia Pacific Association of Gastroenterology ("APAGE").Professor Wu has won a number of awards including the Emerging Leader in Gastroenterology Award by the JGH Foundation, and the Vice Chancellor's Exemplary Teaching Award at CUHK. Aside from his expertise in gastroenterology, Professor Wu has an extensive interest in the development of Integrative Medicine in Hong Kong. He is the Founding Director of the Hong Kong Institute of Integrative Medicine, working closely with the School of Chinese Medicine to develop an integrative model at an international level. The institute aims at maximizing the strength of Western and Chinese medicine to provide a safe and effective integrative treatment to patients.Professor Wu served as a consultant and an advisory board member for Takeda Pharmaceutical, AstraZeneca, Menarini, Reckitt Benckiser and Abbott Laboratory. He earned his Bachelor of Medicine and Bachelor of Surgery Degree (1993), and his Doctor of Medicine Degree (2000) from CUHK. Additionally, he attained Fellowships of the Royal College of Physicians of Edinburgh and London in 2007 and 2012 respectively, Fellowship of the Hong Kong College of Physicians in 2002, Fellowship of the Hong Kong Academy of Medicine in 2002, and has been an American Gastroenterological Association Fellow since 2012.
- Douglas Arner
-
Douglas Arner是知临集团的独立非执行董事。他是香港大学嘉里控股（kerry holdings）法学教授，也是世界领先的金融监管专家之一，尤其是在法律、金融和科技的交叉领域。在香港大学，他是法律系合规与监管法学硕士，公司法和金融法以及法律，创新，技术和创业精英课程法学硕士的系主任。他是墨尔本大学墨尔本法学院（Melbourne Law School，University of Melbourne）的高级客座研究员，以及亚太结构金融协会（the Asia Pacific Structured Finance Association）的执行委员会成员。他领导了世界上最大规模的开放式在线课程MOOC:Fintech入门的开发，该课程于2018年5月在EDX上推出，目前已有超过35000名学习者，遍布世界每个国家。从2006年到2011年，他曾担任HKU&8217；s Asian Institute of International Financial Law（他于1999年共同创立）的董事，并于2012年至2018年领导了一个关于香港作为领先的国际金融中心的未来的重大研究项目。他是香港金融服务发展局（Hong Kong Financial Services Development Council）的创始成员，并于2013年至2019年担任其成员。Douglas从2011年到2014年担任HKU法律系主任，从2005年到2016年担任Duke University-HKU亚美跨国法律研究所联合主任。他出版了15本书和150多篇文章，章节和报告，涉及国际金融法律和监管，包括最近重新概念化全球金融及其监管剑桥2016（与Ross Buckley和Emilios Avgouleas合作）。Regtech Book（即将于2019年与Janos Barberis和Ross Buckley合作）。他最近的论文可在ssrn上获得，网址是https://papers.ssrn.com/sol3/cf_dev/absbyauth.cfm？per_id=524849。
Douglas Arner is an Independent Non Executive Director of Aptorum Group Limited. Douglas is the Kerry Holdings Professor in Law and Director and co founder of the Asian Institute of International Financial Law at the University of Hong Kong, as well as Faculty Director and co founder of the LLM in Compliance and Regulation, LLM in Corporate and Financial Law, and Law, Innovation, Technology and Entrepreneurship (LITE) Programmes. He served as Head of the HKU Department of Law from 2011 to 2014 and as Co Director of the Duke University HKU Asia America Institute in Transnational Law from 2005 to 2016. Douglas has published eighteen books and more than 200 articles, chapters and reports on international financial law and regulation, most recently Reconceptualising Global Finance and its Regulation (Cambridge 2016) (with Ross Buckley and Emilios Avgouleas) and The RegTech Book Wiley 2019 (Janos Barberis and Ross Buckley). His recent papers are available on SSRN at https://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfmper_id=524849, where he is among the top 75 authors in the world by total downloads. Professor Arner led the development of Introduction to FinTech – launched with edX in May 2018 and now with over 80,000 learners spanning the world – and the foundation of the edx HKU Online Professional Certificate in FinTech. He is a Senior Visiting Fellow of Melbourne Law School, University of Melbourne, a non executive director of NASDAQ and Euronext listed Aptorum Group and an Advisory Board Member of the Centre for Finance, Technology and Entrepreneurship (CFTE). Professor Arner was an inaugural member of the Hong Kong Financial Services Development Council (2013 2019) and has served as a consultant with, among others, the World Bank, Asian Development Bank, APEC, Alliance for Financial Inclusion, and European Bank for Reconstruction and Development. He has lectured, co organized conferences and seminars and been involved with financial sector reform projects around the world. Professor Arner has been a visiting professor or fellow at Duke, Harvard, the Hong Kong Institute for Monetary Research, IDC Herzliya, McGill, Melbourne, National University of Singapore, University of New South Wales, Shanghai University of Finance and Economics, and Zurich, among others. Professor Arner is the Senior Regulatory & Strategic Advisor of Aeneas Group, a multi disciplinary financial services institution with technology driven growth initiatives. - Douglas Arner是知临集团的独立非执行董事。他是香港大学嘉里控股（kerry holdings）法学教授，也是世界领先的金融监管专家之一，尤其是在法律、金融和科技的交叉领域。在香港大学，他是法律系合规与监管法学硕士，公司法和金融法以及法律，创新，技术和创业精英课程法学硕士的系主任。他是墨尔本大学墨尔本法学院（Melbourne Law School，University of Melbourne）的高级客座研究员，以及亚太结构金融协会（the Asia Pacific Structured Finance Association）的执行委员会成员。他领导了世界上最大规模的开放式在线课程MOOC:Fintech入门的开发，该课程于2018年5月在EDX上推出，目前已有超过35000名学习者，遍布世界每个国家。从2006年到2011年，他曾担任HKU&8217；s Asian Institute of International Financial Law（他于1999年共同创立）的董事，并于2012年至2018年领导了一个关于香港作为领先的国际金融中心的未来的重大研究项目。他是香港金融服务发展局（Hong Kong Financial Services Development Council）的创始成员，并于2013年至2019年担任其成员。Douglas从2011年到2014年担任HKU法律系主任，从2005年到2016年担任Duke University-HKU亚美跨国法律研究所联合主任。他出版了15本书和150多篇文章，章节和报告，涉及国际金融法律和监管，包括最近重新概念化全球金融及其监管剑桥2016（与Ross Buckley和Emilios Avgouleas合作）。Regtech Book（即将于2019年与Janos Barberis和Ross Buckley合作）。他最近的论文可在ssrn上获得，网址是https://papers.ssrn.com/sol3/cf_dev/absbyauth.cfm？per_id=524849。
- Douglas Arner is an Independent Non Executive Director of Aptorum Group Limited. Douglas is the Kerry Holdings Professor in Law and Director and co founder of the Asian Institute of International Financial Law at the University of Hong Kong, as well as Faculty Director and co founder of the LLM in Compliance and Regulation, LLM in Corporate and Financial Law, and Law, Innovation, Technology and Entrepreneurship (LITE) Programmes. He served as Head of the HKU Department of Law from 2011 to 2014 and as Co Director of the Duke University HKU Asia America Institute in Transnational Law from 2005 to 2016. Douglas has published eighteen books and more than 200 articles, chapters and reports on international financial law and regulation, most recently Reconceptualising Global Finance and its Regulation (Cambridge 2016) (with Ross Buckley and Emilios Avgouleas) and The RegTech Book Wiley 2019 (Janos Barberis and Ross Buckley). His recent papers are available on SSRN at https://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfmper_id=524849, where he is among the top 75 authors in the world by total downloads. Professor Arner led the development of Introduction to FinTech – launched with edX in May 2018 and now with over 80,000 learners spanning the world – and the foundation of the edx HKU Online Professional Certificate in FinTech. He is a Senior Visiting Fellow of Melbourne Law School, University of Melbourne, a non executive director of NASDAQ and Euronext listed Aptorum Group and an Advisory Board Member of the Centre for Finance, Technology and Entrepreneurship (CFTE). Professor Arner was an inaugural member of the Hong Kong Financial Services Development Council (2013 2019) and has served as a consultant with, among others, the World Bank, Asian Development Bank, APEC, Alliance for Financial Inclusion, and European Bank for Reconstruction and Development. He has lectured, co organized conferences and seminars and been involved with financial sector reform projects around the world. Professor Arner has been a visiting professor or fellow at Duke, Harvard, the Hong Kong Institute for Monetary Research, IDC Herzliya, McGill, Melbourne, National University of Singapore, University of New South Wales, Shanghai University of Finance and Economics, and Zurich, among others. Professor Arner is the Senior Regulatory & Strategic Advisor of Aeneas Group, a multi disciplinary financial services institution with technology driven growth initiatives.
- Kira Sheinerman
-
Kira Sheinerman于2009年9月加入DiamiR，是DiamiR的联合创始人和执行董事。谢纳曼博士还是DiamiR，LLC在股份交换前后的执行主席。自2015年11月起，Sheinerman博士担任H.C. Wainwright & Co.，LLC医疗保健投资银行业务董事总经理，负责成长型生命科学公司的财务和战略交易。此前，她曾于2012年至2013年在Burrill & Company担任医疗投资银行业务董事总经理，并于2005年至2012年在Rodman & Renshaw担任董事总经理。在投资银行业务之前，谢纳曼博士曾在生命科学战略咨询公司Arcus集团工作。2010年至2021年，她担任康奈尔大学附属机构Boyce Thompson研究所的董事会成员；2015年至2018年，她担任阿尔茨海默氏症协会商业联盟的联合主席；2020年至2023年，她担任知临集团（纳斯达克股票代码：APM）的高级战略顾问。2008年至2009年，SheNerman博士担任Xenomics（现为Cardiff Oncology；NASDAQ：CRDF）董事会执行委员会主席。谢纳曼博士因其在阿尔茨海默病分子机制方面的工作而获得西奈山医学院生物医学科学博士学位。谢纳曼博士还拥有巴鲁克学院/纽约市立大学Zicklin商学院的荣誉MBA学位。
Kira Sheinerman joined DiamiR in September 2009, and is DiamiR's Co Founder and Executive Director. Dr. Sheinerman was also Executive Chairman of DiamiR, LLC prior to and after the Share Exchange. Since November 2015, Dr. Sheinerman has served as a Managing Director, Healthcare Investment Banking at H.C. Wainwright & Co., LLC, where she works on financial and strategic transactions for growth life sciences companies. Previously, she was a Managing Director of Healthcare Investment Banking at Burrill & Company from 2012 to 2013 and Rodman & Renshaw from 2005 to 2012. Prior to investment banking, Dr. Sheinerman worked at the Arcus group, a life sciences strategic consulting firm. From 2010 to 2021 she served as a board member of the Boyce Thompson Institute, an affiliate of Cornell University; from 2015 through 2018 she served as the co chair of Alzheimer's Association Business Consortium; and from 2020 to 2023 she served as the senior strategic consultant to Aptorum Group (NASDAQ: APM). In 2008 2009, Dr. Sheinerman chaired the Board Executive Committee of Xenomics (now Cardiff Oncology; NASDAQ: CRDF). Dr. Sheinerman received her Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine for her work on molecular mechanisms of Alzheimer's Disease. Dr. Sheinerman also holds an Honors MBA from the Zicklin School of Business, Baruch College/CUNY. - Kira Sheinerman于2009年9月加入DiamiR，是DiamiR的联合创始人和执行董事。谢纳曼博士还是DiamiR，LLC在股份交换前后的执行主席。自2015年11月起，Sheinerman博士担任H.C. Wainwright & Co.，LLC医疗保健投资银行业务董事总经理，负责成长型生命科学公司的财务和战略交易。此前，她曾于2012年至2013年在Burrill & Company担任医疗投资银行业务董事总经理，并于2005年至2012年在Rodman & Renshaw担任董事总经理。在投资银行业务之前，谢纳曼博士曾在生命科学战略咨询公司Arcus集团工作。2010年至2021年，她担任康奈尔大学附属机构Boyce Thompson研究所的董事会成员；2015年至2018年，她担任阿尔茨海默氏症协会商业联盟的联合主席；2020年至2023年，她担任知临集团（纳斯达克股票代码：APM）的高级战略顾问。2008年至2009年，SheNerman博士担任Xenomics（现为Cardiff Oncology；NASDAQ：CRDF）董事会执行委员会主席。谢纳曼博士因其在阿尔茨海默病分子机制方面的工作而获得西奈山医学院生物医学科学博士学位。谢纳曼博士还拥有巴鲁克学院/纽约市立大学Zicklin商学院的荣誉MBA学位。
- Kira Sheinerman joined DiamiR in September 2009, and is DiamiR's Co Founder and Executive Director. Dr. Sheinerman was also Executive Chairman of DiamiR, LLC prior to and after the Share Exchange. Since November 2015, Dr. Sheinerman has served as a Managing Director, Healthcare Investment Banking at H.C. Wainwright & Co., LLC, where she works on financial and strategic transactions for growth life sciences companies. Previously, she was a Managing Director of Healthcare Investment Banking at Burrill & Company from 2012 to 2013 and Rodman & Renshaw from 2005 to 2012. Prior to investment banking, Dr. Sheinerman worked at the Arcus group, a life sciences strategic consulting firm. From 2010 to 2021 she served as a board member of the Boyce Thompson Institute, an affiliate of Cornell University; from 2015 through 2018 she served as the co chair of Alzheimer's Association Business Consortium; and from 2020 to 2023 she served as the senior strategic consultant to Aptorum Group (NASDAQ: APM). In 2008 2009, Dr. Sheinerman chaired the Board Executive Committee of Xenomics (now Cardiff Oncology; NASDAQ: CRDF). Dr. Sheinerman received her Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine for her work on molecular mechanisms of Alzheimer's Disease. Dr. Sheinerman also holds an Honors MBA from the Zicklin School of Business, Baruch College/CUNY.
- Laura A. Philips
-
Laura A. Philips博士，工商管理硕士。2007年5月她获委任为董事。自2009年起，她曾是WellGen公司的董事会成员，并2012年5月任命其首席执行官。WellGen公司是一家早期阶段的生物技术企业，通过严谨的科学支持，开发具有生物活性的天然提取物，为了消费类产品、宠物用品和医疗食品的应用。她担任博伊斯汤普森植物研究所的董事会成员，是一家与美国康奈尔大学相关的生物研究所，联合国人口基金的朋友——这是一个联合国组织，旨在促进世界各地妇女的医疗保健和权利；POGIL项目—— 由美国国家科学基金会支持，用一种创新的方法，以数学和科学教育，并在1000所高校使用的非营利性组织。她担任狄阿莫的顾问委员会成员，这是一个创新的诊断公司，专注于神经退行性疾病。2010年至2011年，她担任中国永新Phamaceuticals（ OTCBB：CYXN）的董事会成员，在中国东北的药品和保健及美容产品的一个领先的零售商、批发商和经销商。2003年至2006年，她是NexGenix制药的首席营运官兼首席财务官，这是一家利基制药初创公司。在加入NexGenix之前，她是AMDeC的副总裁，一家在纽约的生物医药研发联盟。1997年至2002年，她在康宁公司担任过各种管理职务，包括产品开发总监、战略规划和业务经理。她曾在克林顿政府，担任白宫办公室科学和技术政策的研究员,也被总统任命为商务部 Sec Ronald Brown 的高级政策顾问。1994年至1995年，她是国会科学研究员和参议员约瑟夫·利伯曼技术政策的立法顾问。1987年至1993年，她在康奈尔大学的教授化学系。1985年至1987年，她是芝加哥化学系大学的美国国立卫生研究院博士后研究员。她拥有加州大学伯克利分校的化学博士学位，并在康奈尔大学获得工商管理硕士学位。
Laura A. Philips was appointed as a Director in May 2007. Dr. Philips is the Co-Founder, President and CEO of Spheryx, Inc., an analytical services and instruments company with a patented, revolutionary approach to the characterization of colloids, Total Holographic Characterization. Prior to Spheryx she was CEO of WellGen, Inc. from 2012-2014. She serves on the Board of Directors of Boyce Thompson Plant Research Institute, a biological research institute associated with Cornell University and The POGIL Project, a non-profit organization with an innovative approach to math and science education backed by NSF and used in 1000 colleges and universities. She serves on the Advisory Board of Diamer Biosciences, an innovative diagnostics company focused on neurodegenerative disease. From 2010-2011 Dr. Philips served on the board of directors of China Yongxin Phamaceuticals OTCBB:CYXN a leading retailer, wholesaler and distributor of pharmaceuticals and health and beauty products in Northeastern China. From 2003-06 Dr. Philips was Chief Operating Officer and Chief Financial Officer at NexGenix Pharmaceuticals, a niche pharmaceutical start-up company. Prior to joining NexGenix, she was Vice President at AMDeC, a biomedical research and development consortium in New York. She held a variety of executive positions at Corning, Incorporated, from 1997-2002 including director of product development, strategic planning and business manager. Dr. Philips served in the Clinton Administration both as a Fellow in the White House Office of Science and Technology Policy and as a Presidential Appointee to the position of Senior Policy Advisor to Sec Ronald Brown in the Dept. of Commerce. She was Congressional Science Fellow and Legislative Advisor for Technology Policy to Sen. Joseph Lieberman in 1994-5. Dr. Philips was on the Faculty of Cornell University in the Dept of Chemistry from 1987-1993. During the period from 1985 through 1987 she was an NIH Post-Doctoral Fellow at the University of Chicago in the Department of Chemistry. She holds a PhD in Chemistry from the University of California, Berkeley and an MBA from Cornell University. - Laura A. Philips博士，工商管理硕士。2007年5月她获委任为董事。自2009年起，她曾是WellGen公司的董事会成员，并2012年5月任命其首席执行官。WellGen公司是一家早期阶段的生物技术企业，通过严谨的科学支持，开发具有生物活性的天然提取物，为了消费类产品、宠物用品和医疗食品的应用。她担任博伊斯汤普森植物研究所的董事会成员，是一家与美国康奈尔大学相关的生物研究所，联合国人口基金的朋友——这是一个联合国组织，旨在促进世界各地妇女的医疗保健和权利；POGIL项目—— 由美国国家科学基金会支持，用一种创新的方法，以数学和科学教育，并在1000所高校使用的非营利性组织。她担任狄阿莫的顾问委员会成员，这是一个创新的诊断公司，专注于神经退行性疾病。2010年至2011年，她担任中国永新Phamaceuticals（ OTCBB：CYXN）的董事会成员，在中国东北的药品和保健及美容产品的一个领先的零售商、批发商和经销商。2003年至2006年，她是NexGenix制药的首席营运官兼首席财务官，这是一家利基制药初创公司。在加入NexGenix之前，她是AMDeC的副总裁，一家在纽约的生物医药研发联盟。1997年至2002年，她在康宁公司担任过各种管理职务，包括产品开发总监、战略规划和业务经理。她曾在克林顿政府，担任白宫办公室科学和技术政策的研究员,也被总统任命为商务部 Sec Ronald Brown 的高级政策顾问。1994年至1995年，她是国会科学研究员和参议员约瑟夫·利伯曼技术政策的立法顾问。1987年至1993年，她在康奈尔大学的教授化学系。1985年至1987年，她是芝加哥化学系大学的美国国立卫生研究院博士后研究员。她拥有加州大学伯克利分校的化学博士学位，并在康奈尔大学获得工商管理硕士学位。
- Laura A. Philips was appointed as a Director in May 2007. Dr. Philips is the Co-Founder, President and CEO of Spheryx, Inc., an analytical services and instruments company with a patented, revolutionary approach to the characterization of colloids, Total Holographic Characterization. Prior to Spheryx she was CEO of WellGen, Inc. from 2012-2014. She serves on the Board of Directors of Boyce Thompson Plant Research Institute, a biological research institute associated with Cornell University and The POGIL Project, a non-profit organization with an innovative approach to math and science education backed by NSF and used in 1000 colleges and universities. She serves on the Advisory Board of Diamer Biosciences, an innovative diagnostics company focused on neurodegenerative disease. From 2010-2011 Dr. Philips served on the board of directors of China Yongxin Phamaceuticals OTCBB:CYXN a leading retailer, wholesaler and distributor of pharmaceuticals and health and beauty products in Northeastern China. From 2003-06 Dr. Philips was Chief Operating Officer and Chief Financial Officer at NexGenix Pharmaceuticals, a niche pharmaceutical start-up company. Prior to joining NexGenix, she was Vice President at AMDeC, a biomedical research and development consortium in New York. She held a variety of executive positions at Corning, Incorporated, from 1997-2002 including director of product development, strategic planning and business manager. Dr. Philips served in the Clinton Administration both as a Fellow in the White House Office of Science and Technology Policy and as a Presidential Appointee to the position of Senior Policy Advisor to Sec Ronald Brown in the Dept. of Commerce. She was Congressional Science Fellow and Legislative Advisor for Technology Policy to Sen. Joseph Lieberman in 1994-5. Dr. Philips was on the Faculty of Cornell University in the Dept of Chemistry from 1987-1993. During the period from 1985 through 1987 she was an NIH Post-Doctoral Fellow at the University of Chicago in the Department of Chemistry. She holds a PhD in Chemistry from the University of California, Berkeley and an MBA from Cornell University.
高管简历
中英对照 | 中文 | 英文- Gary Anthony
Gary Anthony，他担任公司的首席会计官于2015年4月1日生效。成为首席会计官之前2010年12月以来，他担任公司的财务总监。加入公司之前从2009年10月到2010年10月，他担任Axion International Holdings Inc. （“Axion”）的首席财务官。此前从2009年9月直到他被任命为首席财务官，他担任Axion的财务总监。
Gary Anthony,is an independent consultant providing management and support services to pre-IPO and smaller reporting public companies with respect to accounting, financial reporting, and internal controls. Since November 2022, Mr. Anthony has served the Company as a financial consultant and immediately following the consummation of this offering, he will step into the role of Chief Financial Officer. Since 2022, Mr. Anthony has primarily provided interim controller and financial reporting services to various such companies in pharmaceutical, software, manufacturing, and service industries. From 2020 to 2022 he served as Controller of IPKeys Power Partners and from 2019 to 2020 Controller of Heat Biologics. Previously, he served as Chief Financial Officer of Algos Pharmaceutical Corporation and Axion International and principal accounting officer of Majesco Entertainment and Xenomics. Mr. Anthony earned his BS in Accounting from Monmouth College and initially served on the audit staff of Coopers & Lybrand.- Gary Anthony，他担任公司的首席会计官于2015年4月1日生效。成为首席会计官之前2010年12月以来，他担任公司的财务总监。加入公司之前从2009年10月到2010年10月，他担任Axion International Holdings Inc. （“Axion”）的首席财务官。此前从2009年9月直到他被任命为首席财务官，他担任Axion的财务总监。
- Gary Anthony,is an independent consultant providing management and support services to pre-IPO and smaller reporting public companies with respect to accounting, financial reporting, and internal controls. Since November 2022, Mr. Anthony has served the Company as a financial consultant and immediately following the consummation of this offering, he will step into the role of Chief Financial Officer. Since 2022, Mr. Anthony has primarily provided interim controller and financial reporting services to various such companies in pharmaceutical, software, manufacturing, and service industries. From 2020 to 2022 he served as Controller of IPKeys Power Partners and from 2019 to 2020 Controller of Heat Biologics. Previously, he served as Chief Financial Officer of Algos Pharmaceutical Corporation and Axion International and principal accounting officer of Majesco Entertainment and Xenomics. Mr. Anthony earned his BS in Accounting from Monmouth College and initially served on the audit staff of Coopers & Lybrand.
- Ian Huen
Ian Huen是知临集团的创始人、首席执行官和执行董事。Huen先生自2005年以来也是香港公司Aeneas Capital Limited的联合创始人，Aeneas Capital Limited是一家受香港证券及期货事务监察委员会监管的第9类资产管理公司。他拥有超过17年的全球资产管理经验，此前曾担任Janus Henderson Group plc（前身为Janus Capital）的股票研究分析师，负责美国梦百合行业。Huen先生于二零零七年担任澳门恒生银行有限公司出售予中国工商银行的财务顾问，并获委任为工商银行董事局Vice President及中国商业银行澳门资本有限公司于2007年3月发行，期限12年，至2019年3月止。
Ian Huen is the Founder, Chief Executive Officer and an Executive Director of Aptorum Group Limited. Mr. Huen previous served as Non Executive Director of Aptorum Group from June 2022 to November 2023, and as Chief Executive Officer and Executive Director of Aptorum Group Limited from October 2017 to May 2022. He has extensive experience in global asset management and previously covered the U.S. healthcare sector as an equity research analyst at Janus Henderson Group plc (formerly known as Janus Capital). Mr. Huen was the financial advisor in the sale of Seng Heng Bank Limited (Macau) to Industrial and Commercial Bank of China in 2007 and was appointed as the vice president of the Board of General Meeting in Industrial and Commercial Bank of China (Macau) Capital Limited in March 2007 for a term of 12 years until March 2019. As a trustee board member of the Dr. Stanley Ho Medical Development Foundation, Mr. Huen facilitates advisory, development funding, access to research resources across Asia and continues to establish relationships with leading academic institutions to propel innovations in healthcare.- Ian Huen是知临集团的创始人、首席执行官和执行董事。Huen先生自2005年以来也是香港公司Aeneas Capital Limited的联合创始人，Aeneas Capital Limited是一家受香港证券及期货事务监察委员会监管的第9类资产管理公司。他拥有超过17年的全球资产管理经验，此前曾担任Janus Henderson Group plc（前身为Janus Capital）的股票研究分析师，负责美国梦百合行业。Huen先生于二零零七年担任澳门恒生银行有限公司出售予中国工商银行的财务顾问，并获委任为工商银行董事局Vice President及中国商业银行澳门资本有限公司于2007年3月发行，期限12年，至2019年3月止。
- Ian Huen is the Founder, Chief Executive Officer and an Executive Director of Aptorum Group Limited. Mr. Huen previous served as Non Executive Director of Aptorum Group from June 2022 to November 2023, and as Chief Executive Officer and Executive Director of Aptorum Group Limited from October 2017 to May 2022. He has extensive experience in global asset management and previously covered the U.S. healthcare sector as an equity research analyst at Janus Henderson Group plc (formerly known as Janus Capital). Mr. Huen was the financial advisor in the sale of Seng Heng Bank Limited (Macau) to Industrial and Commercial Bank of China in 2007 and was appointed as the vice president of the Board of General Meeting in Industrial and Commercial Bank of China (Macau) Capital Limited in March 2007 for a term of 12 years until March 2019. As a trustee board member of the Dr. Stanley Ho Medical Development Foundation, Mr. Huen facilitates advisory, development funding, access to research resources across Asia and continues to establish relationships with leading academic institutions to propel innovations in healthcare.
- Alidad Mireskandari
Alidad Mireskandari，于2022年7月加入DiamiR，拥有超过12年的生命科学行业经验，专注于分子诊断测试开发和商业化，包括监管和报销方面的专业知识。Mireskandari博士最近于2013年至2022年担任Interpace生物科学公司的首席开发官，在此之前于2009年至2013年担任JS Genetics公司的总裁兼首席执行官。2000年至2009年，Mireskandari博士担任对冲基金经理，负责野村证券、法国巴黎银行和Raeburn Advisors的生命科学交易组合。在此之前，他曾于1998年至2000年担任PRTM生命科学行业集团的顾问，并于1990年至1996年担任美国国立卫生研究院国家癌症研究所的研究员。Mireskandari博士拥有乔治华盛顿大学的仿制药博士学位和密歇根大学罗斯商学院的MBA学位。
Alidad Mireskandari,joined DiamiR in July 2022, and has over 12 years of life sciences industry experience with a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Dr. Mireskandari most recently served as Chief Development Officer of Interpace Biosciences from 2013 to 2022, and prior to that as President & CEO of JS Genetics from 2009 to 2013. From 2000 to 2009, Dr. Mireskandari was a hedge fund manager in charge of Life Sciences trading portfolios of Nomura Securities, BNP Paribas and Raeburn Advisors. Prior to this experience, he was a consultant with PRTM's life sciences industry group from 1998 to 2000 and a research fellow at National Institutes of Health's National Cancer Institute from 1990 to 1996. Dr. Mireskandari holds his Ph.D. in Generics from George Washington University and his MBA from the University of Michigan Ross School of Business.- Alidad Mireskandari，于2022年7月加入DiamiR，拥有超过12年的生命科学行业经验，专注于分子诊断测试开发和商业化，包括监管和报销方面的专业知识。Mireskandari博士最近于2013年至2022年担任Interpace生物科学公司的首席开发官，在此之前于2009年至2013年担任JS Genetics公司的总裁兼首席执行官。2000年至2009年，Mireskandari博士担任对冲基金经理，负责野村证券、法国巴黎银行和Raeburn Advisors的生命科学交易组合。在此之前，他曾于1998年至2000年担任PRTM生命科学行业集团的顾问，并于1990年至1996年担任美国国立卫生研究院国家癌症研究所的研究员。Mireskandari博士拥有乔治华盛顿大学的仿制药博士学位和密歇根大学罗斯商学院的MBA学位。
- Alidad Mireskandari,joined DiamiR in July 2022, and has over 12 years of life sciences industry experience with a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Dr. Mireskandari most recently served as Chief Development Officer of Interpace Biosciences from 2013 to 2022, and prior to that as President & CEO of JS Genetics from 2009 to 2013. From 2000 to 2009, Dr. Mireskandari was a hedge fund manager in charge of Life Sciences trading portfolios of Nomura Securities, BNP Paribas and Raeburn Advisors. Prior to this experience, he was a consultant with PRTM's life sciences industry group from 1998 to 2000 and a research fellow at National Institutes of Health's National Cancer Institute from 1990 to 1996. Dr. Mireskandari holds his Ph.D. in Generics from George Washington University and his MBA from the University of Michigan Ross School of Business.
- Alidad Mireskandari
Alidad Mireskandari于2022年7月加入DiamiR，拥有超过12年的生命科学行业经验，专注于分子诊断测试开发和商业化，包括监管和报销方面的专业知识。Mireskandari博士最近于2013年至2022年担任Interpace生物科学公司的首席开发官，在此之前于2009年至2013年担任JS Genetics公司的总裁兼首席执行官。2000年至2009年，Mireskandari博士担任对冲基金经理，负责野村证券、法国巴黎银行和Raeburn Advisors的生命科学交易投资组合。在此之前，他曾于1998年至2000年担任PRTM生命科学行业集团的顾问，并于1990年至1996年担任美国国立卫生研究院国家癌症研究所的研究员。Mireskandari博士拥有乔治华盛顿大学的仿制药博士学位和密歇根大学罗斯商学院的MBA学位。
Alidad Mireskandari joined DiamiR in July 2022, and has over 12 years of life sciences industry experience with a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Dr. Mireskandari most recently served as Chief Development Officer of Interpace Biosciences from 2013 to 2022, and prior to that as President & CEO of JS Genetics from 2009 to 2013. From 2000 to 2009, Dr. Mireskandari was a hedge fund manager in charge of Life Sciences trading portfolios of Nomura Securities, BNP Paribas and Raeburn Advisors. Prior to this experience, he was a consultant with PRTM's life sciences industry group from 1998 to 2000 and a research fellow at National Institutes of Health's National Cancer Institute from 1990 to 1996. Dr. Mireskandari holds his Ph.D. in Generics from George Washington University and his MBA from the University of Michigan Ross School of Business.- Alidad Mireskandari于2022年7月加入DiamiR，拥有超过12年的生命科学行业经验，专注于分子诊断测试开发和商业化，包括监管和报销方面的专业知识。Mireskandari博士最近于2013年至2022年担任Interpace生物科学公司的首席开发官，在此之前于2009年至2013年担任JS Genetics公司的总裁兼首席执行官。2000年至2009年，Mireskandari博士担任对冲基金经理，负责野村证券、法国巴黎银行和Raeburn Advisors的生命科学交易投资组合。在此之前，他曾于1998年至2000年担任PRTM生命科学行业集团的顾问，并于1990年至1996年担任美国国立卫生研究院国家癌症研究所的研究员。Mireskandari博士拥有乔治华盛顿大学的仿制药博士学位和密歇根大学罗斯商学院的MBA学位。
- Alidad Mireskandari joined DiamiR in July 2022, and has over 12 years of life sciences industry experience with a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Dr. Mireskandari most recently served as Chief Development Officer of Interpace Biosciences from 2013 to 2022, and prior to that as President & CEO of JS Genetics from 2009 to 2013. From 2000 to 2009, Dr. Mireskandari was a hedge fund manager in charge of Life Sciences trading portfolios of Nomura Securities, BNP Paribas and Raeburn Advisors. Prior to this experience, he was a consultant with PRTM's life sciences industry group from 1998 to 2000 and a research fellow at National Institutes of Health's National Cancer Institute from 1990 to 1996. Dr. Mireskandari holds his Ph.D. in Generics from George Washington University and his MBA from the University of Michigan Ross School of Business.
- Kira Sheinerman
Kira Sheinerman于2009年9月加入DiamiR，是DiamiR的联合创始人和执行董事。谢纳曼博士还是DiamiR，LLC在股份交换前后的执行主席。自2015年11月起，Sheinerman博士担任H.C. Wainwright & Co.，LLC医疗保健投资银行业务董事总经理，负责成长型生命科学公司的财务和战略交易。此前，她曾于2012年至2013年在Burrill & Company担任医疗投资银行业务董事总经理，并于2005年至2012年在Rodman & Renshaw担任董事总经理。在投资银行业务之前，谢纳曼博士曾在生命科学战略咨询公司Arcus集团工作。2010年至2021年，她担任康奈尔大学附属机构Boyce Thompson研究所的董事会成员；2015年至2018年，她担任阿尔茨海默氏症协会商业联盟的联合主席；2020年至2023年，她担任知临集团（纳斯达克股票代码：APM）的高级战略顾问。2008年至2009年，SheNerman博士担任Xenomics（现为Cardiff Oncology；NASDAQ：CRDF）董事会执行委员会主席。谢纳曼博士因其在阿尔茨海默病分子机制方面的工作而获得西奈山医学院生物医学科学博士学位。谢纳曼博士还拥有巴鲁克学院/纽约市立大学Zicklin商学院的荣誉MBA学位。
Kira Sheinerman joined DiamiR in September 2009, and is DiamiR's Co Founder and Executive Director. Dr. Sheinerman was also Executive Chairman of DiamiR, LLC prior to and after the Share Exchange. Since November 2015, Dr. Sheinerman has served as a Managing Director, Healthcare Investment Banking at H.C. Wainwright & Co., LLC, where she works on financial and strategic transactions for growth life sciences companies. Previously, she was a Managing Director of Healthcare Investment Banking at Burrill & Company from 2012 to 2013 and Rodman & Renshaw from 2005 to 2012. Prior to investment banking, Dr. Sheinerman worked at the Arcus group, a life sciences strategic consulting firm. From 2010 to 2021 she served as a board member of the Boyce Thompson Institute, an affiliate of Cornell University; from 2015 through 2018 she served as the co chair of Alzheimer's Association Business Consortium; and from 2020 to 2023 she served as the senior strategic consultant to Aptorum Group (NASDAQ: APM). In 2008 2009, Dr. Sheinerman chaired the Board Executive Committee of Xenomics (now Cardiff Oncology; NASDAQ: CRDF). Dr. Sheinerman received her Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine for her work on molecular mechanisms of Alzheimer's Disease. Dr. Sheinerman also holds an Honors MBA from the Zicklin School of Business, Baruch College/CUNY.- Kira Sheinerman于2009年9月加入DiamiR，是DiamiR的联合创始人和执行董事。谢纳曼博士还是DiamiR，LLC在股份交换前后的执行主席。自2015年11月起，Sheinerman博士担任H.C. Wainwright & Co.，LLC医疗保健投资银行业务董事总经理，负责成长型生命科学公司的财务和战略交易。此前，她曾于2012年至2013年在Burrill & Company担任医疗投资银行业务董事总经理，并于2005年至2012年在Rodman & Renshaw担任董事总经理。在投资银行业务之前，谢纳曼博士曾在生命科学战略咨询公司Arcus集团工作。2010年至2021年，她担任康奈尔大学附属机构Boyce Thompson研究所的董事会成员；2015年至2018年，她担任阿尔茨海默氏症协会商业联盟的联合主席；2020年至2023年，她担任知临集团（纳斯达克股票代码：APM）的高级战略顾问。2008年至2009年，SheNerman博士担任Xenomics（现为Cardiff Oncology；NASDAQ：CRDF）董事会执行委员会主席。谢纳曼博士因其在阿尔茨海默病分子机制方面的工作而获得西奈山医学院生物医学科学博士学位。谢纳曼博士还拥有巴鲁克学院/纽约市立大学Zicklin商学院的荣誉MBA学位。
- Kira Sheinerman joined DiamiR in September 2009, and is DiamiR's Co Founder and Executive Director. Dr. Sheinerman was also Executive Chairman of DiamiR, LLC prior to and after the Share Exchange. Since November 2015, Dr. Sheinerman has served as a Managing Director, Healthcare Investment Banking at H.C. Wainwright & Co., LLC, where she works on financial and strategic transactions for growth life sciences companies. Previously, she was a Managing Director of Healthcare Investment Banking at Burrill & Company from 2012 to 2013 and Rodman & Renshaw from 2005 to 2012. Prior to investment banking, Dr. Sheinerman worked at the Arcus group, a life sciences strategic consulting firm. From 2010 to 2021 she served as a board member of the Boyce Thompson Institute, an affiliate of Cornell University; from 2015 through 2018 she served as the co chair of Alzheimer's Association Business Consortium; and from 2020 to 2023 she served as the senior strategic consultant to Aptorum Group (NASDAQ: APM). In 2008 2009, Dr. Sheinerman chaired the Board Executive Committee of Xenomics (now Cardiff Oncology; NASDAQ: CRDF). Dr. Sheinerman received her Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine for her work on molecular mechanisms of Alzheimer's Disease. Dr. Sheinerman also holds an Honors MBA from the Zicklin School of Business, Baruch College/CUNY.